Track Dr. Lal Pathlabs Ltd.'s current share price, historical price chart, 52-week high/low, and performance across different time periods.
1 Week returns: -3.07 %
Low
1,610.1
High
1,698.5
1 Month returns: 4.43 %
Low
1,500.0
High
1,803.6
1 Year returns: 18.95 %
Low
1,272.0
High
1,803.6
3 Year CAGR: 13.08 %
Low
971.9
High
1,827.0
5 Year CAGR: -0.36 %
Low
881.0
High
2,122.8
Note: Prices may be delayed by a few minutes. For historical calculations, prices are adjusted for splits, bonus and rights issue. Percentage change shown is absolute irrespective of the period.
Multi-year trends for Dr. Lal Pathlabs Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.
Dr. Lal Pathlabs Ltd. Shareholding Pattern
Quarterly breakdown of Dr. Lal Pathlabs Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.
Bulk, Block and Insider Trades
Recent bulk deals, block deals, and insider trading activity in Dr. Lal Pathlabs Ltd. shares as reported to NSE and BSE.
Frequently Asked Questions
What is the current share price of Dr. Lal Pathlabs Ltd.?
The current share price of Dr. Lal Pathlabs Ltd. is ₹ 1,639.10 as of 3 Jul 2026.
What is the market capitalisation of Dr. Lal Pathlabs Ltd.?
The market capitalisation of Dr. Lal Pathlabs Ltd. stands at ₹ 27,531.70 Cr.
What is the PE ratio of Dr. Lal Pathlabs Ltd.?
The Price-to-Earnings (PE) ratio of Dr. Lal Pathlabs Ltd. is 54.54 as of the latest trailing twelve months data.
What is the ROE and ROCE of Dr. Lal Pathlabs Ltd.?
Dr. Lal Pathlabs Ltd. has a Return on Equity (ROE) of 21.57% and a Return on Capital Employed (ROCE) of 24.32% as per the latest financial reports.
What is the 52-week high and low of Dr. Lal Pathlabs Ltd.?
The 52-week high of Dr. Lal Pathlabs Ltd. is - and the 52-week low is -.
What is the dividend yield of Dr. Lal Pathlabs Ltd.?
The dividend yield of Dr. Lal Pathlabs Ltd. is 0.79% based on the current market price.
What is the FII and DII holding in Dr. Lal Pathlabs Ltd.?
Foreign Institutional Investors (FII) hold 17.18%, Domestic Institutional Investors (DII) hold 20.95% and retail/public investors hold 7.83% of Dr. Lal Pathlabs Ltd. shares.
What sector does Dr. Lal Pathlabs Ltd. belong to?
Dr. Lal Pathlabs Ltd. operates in the Healthcare sector. 84% of analysts have a Buy or Strong Buy rating on Dr. Lal Pathlabs Ltd. with a consensus target price of ₹ 1,700.00, implying 3.16% upside from current levels.
What is the beta of Dr. Lal Pathlabs Ltd.?
The beta of Dr. Lal Pathlabs Ltd. is 0.50, indicating its price volatility relative to the broader market. Over the past 1 year, Dr. Lal Pathlabs Ltd. has delivered an absolute return of 20.41%.
What is the RSI of Dr. Lal Pathlabs Ltd.?
The 14-day Relative Strength Index (RSI) of Dr. Lal Pathlabs Ltd. is 55.12, placing it in the neutral zone. An RSI above 70 is considered overbought and below 30 is considered oversold.
Stock Analysis
Fundamental analysis overview of Dr. Lal Pathlabs Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.
Views
Red Flags
Positive
Strong price momentum
Price Momentum score of 84.3 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term
What is Price Momentum score?
84.3 / 100
High and stable operating margin
The company reported strong operating margin of 22.47% for 12-month ended 31 Mar 2026 and operating margin declined marginally by -10 bps from 1 year ago
What is Operating profit margin?
Low Debt to Equity, not much change from last year
The company has low Debt to Equity of 0.08 as on 31 Mar 2026 and Debt to Equity increased marginally by 0.01 in the last 1 year
What is Debt to Equity?
Consistently pays dividend
The company has not missed dividend payments once in the last 10 financial years
What is Dividend streak?
Company is net cash
The company is net cash i.e., cash and cash equivalents exceed total debt indicating a healthy balance sheet
What is Net Debt ?
Negative
Expensive and at a premium to industry median P/E
PE TTM of 54.54 indicates that the stock is expensive on a standalone basis and is at a 96.82% premium to industry median P/E
What is P/E Ratio?
Median: 27.71
Value 54.54
6.282638.46
Analysts have been downgrading forward EPS estimates
Analyst EPS estimate (consensus) for forward EPS has decreased by -0.23% in the last 3 months, indicating weak earnings momentum
What is Earnings upgrade (3M)?
Low dividend yield
The company has a low dividend yield of 0.79%
What is Dividend yield?
Neutral
High ROE but declining trend
The company reported strong ROE of 21.57% for 12-month ended 31 Mar 2026 but ROE declined by -265 bps from 1 year ago
What is ROE (FY)?
Moderate revenue growth and in line with median growth of industry
The company delivered moderate revenue growth of 12.25% for 12-month ended 31 Mar 2026 and the growth was 1.31 percentage points lower than median growth of industry
What is Sales growth (1Y)?
Median: 13.56
Value 12.25
-97.35238.8
Low EPS growth but above median growth of industry
The company delivered low EPS growth of 3.43% for 12-month ended 31 Mar 2026 but the growth was 2.29 percentage points higher than median growth of industry
What is EPS growth (1Y)?
Company's earnings are of moderate quality
Earnings quality score of 65.6 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion
What is Earnings quality score?
65.6 / 100
No red flags found!
No significant red flags found in the stock.
Net Revenue FY
Profit After Tax FY
ROE FY
EBITDA FY
Company Profile
Overview of Dr. Lal Pathlabs Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.
Dr. Lal PathLabs Limited is an India-based provider of diagnostic and related healthcare tests and services. The Company is engaged primarily in the business of running laboratories for carrying out pathological investigations in various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It offers a range of tests, including Pregnancy Test, Full Body Checkups, Covid 19 Test, Heart Test, Kidney Test, Liver Test, Cholesterol Test, Hepatitis B Test, Kidney Function Test, Sugar Test, Thyroid Test, Typhoid Test, Uric Acid Test, Vitamin B12 Test and vitamin D Test. It has approximately 298 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab in Kolkata, Bangalore and Mumbai), 6,607 patient service centers, and 12,365 pick-up points (PUPs). Its customers include individual patients, hospitals, and corporate customers.
Dr. Lal PathLabs Limited is an India-based provider of diagnostic and related healthcare tests and services. The Company is engaged primarily in the business of running laboratories for carrying out pathological investigations in various branches of bio-chemistry, hematology, histopathology, microbi...
Key personnel
Mr. Shankha Banerjee
Chief Executive Officer
Mr. Ved Prakash Goel
Group Chief Financial Officer and Chief Executive Officer - International Business